LISTEN LIVE: Morning Edition



Is There A Pickup Coming For Biotech IPOs?04:44

This article is more than 5 years old.

It’s been a relatively slow year for the U.S. biotech sector. So far, only 16 companies nationwide have gone public since January.

That’s about half as many as during the boom years between 2013 and 2015.

But the last couple of weeks have seen four IPOs, including two here in Massachusetts, for the firms Mersana and Aileron. Both are focused on cancer drugs.

For a look at the dry spell, and what might be driving the possible shift underway, we spoke to Luke Timmerman, founder and editor of the biotech industry newsletter the Timmerman Report.

This segment aired on July 10, 2017.

Bob Oakes Twitter Senior Correspondent
Bob Oakes was a senior correspondent in the WBUR newsroom, a role he took on in 2021 after nearly three decades hosting WBUR's Morning Edition.